Antibodies that neutralize sclerostin (Scl-Ab) or DKK-1 (DKK1-Ab) are being evaluated as potential therapies to treat bone disorders such as post-menopausal osteoporosis and myeloma-induced bone disease16, 17, 18, 19, 20, 21. This evidence concerns the gene DKK1 and plasma cell myeloma.